Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, is an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

“We had a cohort of 21 patients, one-third of which [had] 

 rearrangements. [In this population], the overall response rate was high, [at 86%]. The complete response [CR]/CR with partial hematologic recovery rate was also [86%].”

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed findings from the phase 2 SAVE trial (NCT05360160) evaluating revumenib (Revuforj) plus decitabine, cedazuridine, and venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


ASH Annual Meeting and Exposition

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.